Navigation Links
University Evaluates New Device To Treat Brain Tumors

The University of Illinois at Chicago has enrolled the first patient in the United States in a study of a new treatment for the most common and aggressive type of brain// tumor.

The international, multi-center trial will compare the best standard treatments -- surgical removal of the tumor, radiotherapy or chemotherapy -- to that treatment combined with a new, noninvasive therapy that provides alternating electrical fields directly to the surface of the head.

"This therapy is a totally novel approach that is, in concept, relatively simple," said Dr. Herbert Engelhard, associate professor of neurosurgery and site investigator for the trial at UIC.

Following a baseline MRI to determine the location of the tumor, several electrodes are placed on the patient's shaved head. The electrodes are connected to a medical device with alternating electric fields powered by a portable battery. The patient remains on the portable device for 22 hours a day, indefinitely, while continuing his or her daily activities at home.

"Research has shown that these electrical fields rupture the cancer cells as they divide," Engelhard said.

While likely not a cure for the deadly tumor, called glioblastoma multiforme, the therapy, Engelhard says, may extend life for some people. In an earlier small-scale study, the therapy more than doubled survival for glioblastoma patients.

Glioblastoma multiforme is the most deadly of all intracranial tumors. Standard therapy does not provide a cure and often results in side effects that compromise a patient's quality of life. Despite attempts to improve outcome, the current three-year survival is only 6 percent.

"Patients with recurrent glioblastoma whose tumor progresses despite radiation treatment and chemotherapy do not have many options," Engelhard said. "Therefore, it's critical that we consider new therapies for the treatment of this disease."

Fifty-one-ye ar-old Daniel Torres of Chicago is a pioneer, according to Engelhard. Torres is the first person in the United States randomized to receive the novel therapy.

On Nov. 15 Torres had 36 electrodes placed on his head to emit very low intensity, intermediate frequency electric fields called tumor-treating fields. He was kept in the hospital overnight for observation and discharged the next day.

Torres, a father of four, ages 6 to 16, says the therapy may offer him a second chance at life. He has had three surgeries, chemotherapy, radiation and radiotherapy since he was first diagnosed with glioblastoma multiforme nearly three years ago.

He says he is hopeful for himself, but also for future patients who may benefit from the study.

The trial will enroll 236 patients at 10 U.S. centers and seven in Europe. Half the patients will receive continuous therapy with the NovoTTF-100A in addition to standard treatment and will be evaluated every four weeks; the other half will receive the standard treatment alone. All patients in the study will be evaluated for disease progression.

Source-Newswise
'"/>




Related medicine news :

1. Researchers at Cornell University as been reported using research fund by false claims
2. A new study by John Hopkins University proposes formula for good health
3. James Cook University urges more medical seats
4. Pill splitting program of University of Michigan can save money
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Yale University guidelines for Physicians and Pharmaceutical industry
7. $ 1.7 Million NYSTAR Award for Binghamton University to Flex Electronics Research Muscle.
8. Florida State University declares a breathtaking study which might solve the Hepatitis C Virus maze and find a cure!
9. Hwang Woo Suk Suspended By Seoul National University
10. Vladeck to head the University of Medicine and Dentistry of New Jersey
11. Rice University wins Prestigious Grants from HHMI
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... ... ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor Brian Sandoval, ... Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday to dedicate ... be the first Fisher House in Nevada, and will provide free lodging for families ...
(Date:2/12/2016)... ... 2016 , ... Young Asset Protection, a full service insurance ... latest charity campaign in their community enrichment program. Art Expression utilizes after-school programs ... are currently being accepted at: http://artexpressioninc.org/ . , Art Expression is a ...
(Date:2/12/2016)... ... 12, 2016 , ... Mediaplanet today announces the launch of ... of “Revolutionizing Cancer Care” is distributed within the February 12 issue of USA ... circulation of approximately 250,000 copies and an estimated readership of 750,000 readers. The ...
(Date:2/12/2016)... ... 12, 2016 , ... A lot has been reported about the fitness routines ... to health and wellness resources most Americans could ever dream of having at their ... schedule as frenetic as the U.S. President. , In honor of President’s Day ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Basketball is ... and integral part of the Peety PoppersTM series, sign language translation is featured in ... of health and wellness in Peety PoppersTM lessons has a sign language translator to ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016 On Thursday, Feb. ... Surgery at St. David,s North Austin Medical Center successfully ... ® Xi ® Surgical System with Trumpf ... Thiru Lakshman , M.D., colorectal surgeon at ... proctocolectomy utilizing Integrated Table Motion technology, which seamlessly combines ...
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
Breaking Medicine Technology: